Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Ironwood Pharmaceuticals (IRWD) over the last 14 years, with Q3 2025 value amounting to $638.0 million.

  • Ironwood Pharmaceuticals' Total Non-Current Liabilities fell 349.14% to $638.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $638.0 million, marking a year-over-year decrease of 349.14%. This contributed to the annual value of $635.1 million for FY2024, which is 1949.61% down from last year.
  • According to the latest figures from Q3 2025, Ironwood Pharmaceuticals' Total Non-Current Liabilities is $638.0 million, which was down 349.14% from $628.6 million recorded in Q2 2025.
  • In the past 5 years, Ironwood Pharmaceuticals' Total Non-Current Liabilities registered a high of $919.0 million during Q2 2023, and its lowest value of $436.3 million during Q2 2022.
  • Moreover, its 5-year median value for Total Non-Current Liabilities was $628.6 million (2025), whereas its average is $603.4 million.
  • As far as peak fluctuations go, Ironwood Pharmaceuticals' Total Non-Current Liabilities soared by 11061.85% in 2023, and later tumbled by 2571.96% in 2024.
  • Ironwood Pharmaceuticals' Total Non-Current Liabilities (Quarter) stood at $517.5 million in 2021, then fell by 15.29% to $438.4 million in 2022, then skyrocketed by 79.97% to $789.0 million in 2023, then dropped by 19.5% to $635.1 million in 2024, then increased by 0.45% to $638.0 million in 2025.
  • Its Total Non-Current Liabilities stands at $638.0 million for Q3 2025, versus $628.6 million for Q2 2025 and $644.0 million for Q1 2025.